A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (POWER)

Investigator: Bincy Abraham, MD

Study Coordinator: Alejandro De La Torre

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT03782376

Phone: 713.441.6396

Protocol Number: Pro00021111


The primary purpose of this study is to evaluate the efficacy and safety of a single intravenous (IV) re-induction dose of approximately 6 milligram per kilogram (mg/kg) ustekinumab in participants with secondary loss of response (LoR) to subcutaneous (SC) every 8 Weeks (q8w) 90 mg ustekinumab maintenance therapy.
More to Explore